logo-loader

Midatech receives £450,000 payment as part of vaccines deal

Published: 07:24 22 Nov 2016 GMT

shutterstock_228844273
The company has received a financial boost from its collaboration.

Midatech Pharma Plc (LOM:MTPH, NASDAQ:MTP) said it had received £450,000 under the terms of its contract with Emergex Vaccines.

The latter is using the former’s gold nanoparticle platform to develop of vaccines for flu, meningitis, bacterial pneumonia, Ebola and a number of other infectious diseases. This is the first deployment of the technology in this setting.

"I am pleased to see progress being made in the adaptation of our gold nanoparticle technology for use in vaccines for infectious disease,” said chief executive Jim Phillips.

 “[This] perfectly complements our type 1 diabetes collaboration in antigen specific immunotherapy, and our early-stage internal programs which address auto-immune disease and immuno-oncology."

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 35 minutes ago